Insulin Actrapid HM
Insulin Actrapid HM is an originator product from Novo Nordisk Pharma AG and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 28.70 to CHF 28.70 depending on the pack; the patient co-payment is 10 per cent plus the deductible.
Core data
- Authorisation holder
- Novo Nordisk Pharma AG
- ATC code
- A10AB01
- IT group
- 07.06.10 Insuline
- Active substances
- Insulinum humanum ADNr solutum
- Preparation type
- Originator product
- On the SL since
- 15/03/1988
- Last price change
- 01/12/2023
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Inj Lös 100 IE/ml | Durchstf 10 ml | CHF 11.30 | CHF 28.70 | 01/07/2019 | B | 7680446100354 |
Limitation
No limitation is recorded on the SL for this preparation.
FAQ
Is Insulin Actrapid HM covered by Swiss health insurance?
Yes. Insulin Actrapid HM is on the FOPH Specialities List, so Swiss mandatory health insurance reimburses it within the authorised indication. You still pay the deductible and a co-payment of 10 per cent.
What does Insulin Actrapid HM cost in Switzerland?
The public price is the maximum price set by the FOPH and for Insulin Actrapid HM ranges from CHF 28.70 to CHF 28.70 per pack. The ex-factory price ranges from CHF 11.30 to CHF 11.30. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages